{"protocolSection": {"identificationModule": {"nctId": "NCT01218399", "orgStudyIdInfo": {"id": "SU-10042010-7010"}, "secondaryIdInfos": [{"id": "IRB 15128"}], "organization": {"fullName": "Stanford University", "class": "OTHER"}, "briefTitle": "Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations", "officialTitle": "A Randomized, Blinded, Single-center Study in Mild to Moderate Asthmatics Over the Age of 12 Years Who Have a Viral-mediated Exacerbation and Are Treated With Symbicort or Pulmicort Flexhaler"}, "statusModule": {"statusVerifiedDate": "2017-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-09"}, "primaryCompletionDateStruct": {"date": "2010-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-10-07", "studyFirstSubmitQcDate": "2010-10-08", "studyFirstPostDateStruct": {"date": "2010-10-11", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-01-23", "resultsFirstSubmitQcDate": "2017-07-18", "resultsFirstPostDateStruct": {"date": "2017-08-18", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-07-18", "lastUpdatePostDateStruct": {"date": "2017-08-18", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Kari Christine Nadeau", "investigatorTitle": "Principle Investigator", "investigatorAffiliation": "Stanford University"}, "leadSponsor": {"name": "Stanford University", "class": "OTHER"}, "collaborators": [{"name": "AstraZeneca", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This is an investigator-initiated study in which Dr. Nadeau wrote the protocol and received funding from an Astra Zeneca grant to direct, perform, and monitor the study on her own with Stanford staff. We hypothesize that the budesonide/formoterol combination improves the efficacy of budesonide alone.", "detailedDescription": "The study was designed such that 30 participants would be consented/enrolled into the trial. The intervention would only be applied if the participant developed a viral illness that met eligibility criteria during the study period.\n\nOnly 10 of the 30 ppt. consented/enrolled developed a virus and were then treated according to study arm.\n\nA more detailed description can be obtained by contacting Astra Zeneca"}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["PARTICIPANT"]}}, "enrollmentInfo": {"count": 10, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Budesonide", "type": "ACTIVE_COMPARATOR", "description": "Combination of budesonide and formoterol. Medications are given according to the package insert and manufacturer's instructions.\n\nParticipants that develop a viral upper respiratory illness which induces an asthma exacerbation.within the specified period following enrollment, are randomly assigned 1:1 to either study arm. 5 participants were randomly assigned to the Symbicort study arm.", "interventionNames": ["Drug: Symbicort"]}, {"label": "Placebo Comparator: Budesonide", "type": "PLACEBO_COMPARATOR", "description": "Control of budesonide alone. Medication was given according to the package insert and manufacturer's instructions.\n\nParticipants that develop a viral upper respiratory illness which induces an asthma exacerbation.within the specified period following enrollment, are randomly assigned 1:1 to either study arm. 5 participants were randomly assigned to the Budesonide study arm.", "interventionNames": ["Drug: Symbicort"]}], "interventions": [{"type": "DRUG", "name": "Symbicort", "armGroupLabels": ["Budesonide", "Placebo Comparator: Budesonide"], "otherNames": ["Budesonide"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percent Forced Expiratory Volume in One Second (FEV1)", "description": "Asthma symptoms scores reported as measure of FEV1 - Forced Expiratory Volume in one second\n\n* FEV1 is given which is a standard outcome in asthma studies and is validated by the NIH (NHLBI)\n* FEV1 of less than 80 is indicative of severe asthma, 80-90 is moderate asthma, over 90 is mild asthma\n\nhttp://www.med.umich.edu/1info/FHP/practiceguides/asthma/EPR-3_pocket_guide.pdf", "timeFrame": "1 week"}], "secondaryOutcomes": [{"measure": "Adverse Events", "description": "Number of adverse events as per MEDRA terms", "timeFrame": "1 week"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nSubjects will be considered for inclusion in this study based on meeting all of the following criteria:\n\n1. Male or female, aged 12 to 65 years\n2. Subjects with mild to moderate asthma as determined by NHLBI 2007 guidelines\n3. Subjects with exacerbation of their asthma symptoms by NHLBI 2007 guidelines\n4. IgE level at study entry less than 50 IU/mL\n5. Men and women of reproductive potential who document use of adequate contraception during the study and for 3 months after the conclusion of treatment with study drug/placebo\n6. Historical documentation of asthma in the patient's medical record. The patient should have 6 months or more of asthma medication and management by a Stanford physician.\n7. Women of childbearing potential who have a negative pregnancy test (urine or serum) at the time of study entry\n8. Subject's guardians who are capable of understanding the purpose and risks of the study and who sign a statement of informed consent for the study\n\nExclusion Criteria:\n\nSubjects will be ineligible for this study based on any one of the following criteria:\n\n1. With a chronic or acute disease that might interfere with the evaluation of Symbicort or Pulmicort Flexhaler therapy\n2. Pregnancy or lactation\n3. Current or prior malignancies (excluding non-melanoma skin carcinoma or carcinoma in situ of the cervix that has been adequately treated)\n4. History of infection with human immunodeficiency virus (HSC-1), hepatitis B virus (HBV), or hepatitis C virus (HCV); or Hepatitis A virus (HAV)\n5. Infections that require intravenous antibiotic therapy\n6. Significant organ dysfunction, including cardiac, renal, liver, CNS, pulmonary, vascular, gastrointestinal, endocrine, or metabolic (e.g., creatinine \\>1.6 mg/dL; ALT or AST \\> 1.5x the upper limit of normal; history of myocardial infarction, congestive heart failure, or arrhythmias within 6 months prior to study entry)\n7. Treatment with a humanized or chimeric antibody therapy within 4 weeks prior to study entry\n8. Treatment with any investigational drugs or therapies within 2 weeks prior to study entry\n9. Any use of oral, systemic corticosteroids within 2 weeks prior to study entry", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "maximumAge": "65 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Kari Christine Nadeau", "affiliation": "Stanford University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Stanford University School of Medicine", "city": "Stanford", "state": "California", "zip": "94305", "country": "United States", "geoPoint": {"lat": 37.42411, "lon": -122.16608}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants that contract a viral upper respiratory illness which induces an asthma exacerbation and meets eligibility criteria will be randomized at Day 1 to either Symbicort or Budesonide in a 1:1 randomization. 5 participants were randomly assigned to the Symbicort study arm, and 5 participants were assigned to the Budesonide study arm.", "groups": [{"id": "FG000", "title": "Symbicort", "description": "Combination of budesonide and formoterol\n\nSymbicort will be given as per product insert (2 puffs twice daily of 160/4.5 Budesonide/formoterol)"}, {"id": "FG001", "title": "Budesonide", "description": "Control of budesonide alone\n\nPulmicort Flexhaler will be given as per product insert (2 puffs twice daily of 160 mcg)"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Symbicort", "description": "combination of budesonide and formoterol\n\nSymbicort vs Budesonide in treating acute respiratory illness: use of either symbicort or budesonide"}, {"id": "BG001", "title": "Budesonide", "description": "control of budesonide alone\n\nSymbicort vs Budesonide in treating acute respiratory illness: use of either symbicort or budesonide"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "10"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "10"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "24", "spread": "5"}, {"groupId": "BG001", "value": "25", "spread": "6"}, {"groupId": "BG002", "value": "24", "spread": "5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "5"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "10"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percent Forced Expiratory Volume in One Second (FEV1)", "description": "Asthma symptoms scores reported as measure of FEV1 - Forced Expiratory Volume in one second\n\n* FEV1 is given which is a standard outcome in asthma studies and is validated by the NIH (NHLBI)\n* FEV1 of less than 80 is indicative of severe asthma, 80-90 is moderate asthma, over 90 is mild asthma\n\nhttp://www.med.umich.edu/1info/FHP/practiceguides/asthma/EPR-3_pocket_guide.pdf", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "% FEV1", "timeFrame": "1 week", "groups": [{"id": "OG000", "title": "Symbicort", "description": "combination of budesonide and formoterol\n\nSymbicort vs Budesonide in treating acute respiratory illness: use of either symbicort or budesonide"}, {"id": "OG001", "title": "Budesonide", "description": "control of budesonide alone\n\nSymbicort vs Budesonide in treating acute respiratory illness: use of either symbicort or budesonide"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "90", "spread": "13"}, {"groupId": "OG001", "value": "88", "spread": "14"}]}]}]}, {"type": "SECONDARY", "title": "Adverse Events", "description": "Number of adverse events as per MEDRA terms", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number adverse events", "timeFrame": "1 week", "groups": [{"id": "OG000", "title": "Symbicort", "description": "combination of budesonide and formoterol\n\nSymbicort vs Budesonide in treating acute respiratory illness: use of either symbicort or budesonide"}, {"id": "OG001", "title": "Budesonide", "description": "control of budesonide alone\n\nSymbicort vs Budesonide in treating acute respiratory illness: use of either symbicort or budesonide"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Data was collected for a year", "eventGroups": [{"id": "EG000", "title": "Symbicort", "description": "combination of budesonide and formoterol\n\nSymbicort vs Budesonide in treating acute respiratory illness: use of either symbicort or budesonide", "deathsNumAffected": 0, "deathsNumAtRisk": 10, "seriousNumAffected": 0, "seriousNumAtRisk": 10, "otherNumAffected": 0, "otherNumAtRisk": 10}, {"id": "EG001", "title": "Budesonide", "description": "control of budesonide alone\n\nSymbicort vs Budesonide in treating acute respiratory illness: use of either symbicort or budesonide", "deathsNumAffected": 0, "deathsNumAtRisk": 10, "seriousNumAffected": 0, "seriousNumAtRisk": 10, "otherNumAffected": 0, "otherNumAtRisk": 10}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Please contact the sponsor Astra Zeneca for the agreement"}, "pointOfContact": {"title": "Elena Pizzi", "organization": "Astra Zeneca", "email": "Elena.Pizzi@astrazeneca.com", "phone": "+1 302 885 2677"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019819", "term": "Budesonide"}, {"id": "D000069502", "term": "Budesonide, Formoterol Fumarate Drug Combination"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "asFound": "Of 1", "relevance": "HIGH"}, {"id": "M304", "name": "Formoterol Fumarate", "relevance": "LOW"}, {"id": "M452", "name": "Budesonide, Formoterol Fumarate Drug Combination", "asFound": "Early Stage", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}